[PDF] Top 20 Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
Has 10000 "Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes." found on our website. Below are the top 20 most common "Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.".
Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
... and PD-1 inhibition exhibiting greater inhibitory effect on tumour growth compared to PD1 inhibition or MEK inhibition alone ...activating PD-1/PD-L1 checkpoint through EGFR/MAPK ... See full document
42
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
... to immunotherapy [97, ...to PD-1 blockade ...of PD-L1 can be detected in the tumor ...express PD-L1 [101]. In these two cases, the clinical activity of ... See full document
21
<p>The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy</p>
... years, immunotherapy targeting immune checkpoints has shed a light on cancer ...protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 ...course. 1 To date, there are several ... See full document
9
Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma
... regular clinical and laboratory examinations as follows: every 3 months for the first 2 years, every 6 months for the following 2 years, and annually for an additional 5 years or until patient death, whichever ... See full document
12
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
... vide clinical benefits in patients with melanoma and some other ...of PD-L1 ...tremelimumab immunotherapy for untreated patients with advanced or metastatic NSCLC and wild-type EGFR and ALK, ... See full document
8
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
... with clinical benefit to PD-1 and CTLA-4 inhibitors in NSCLC and melanoma respectively (Snyder et al, 2014; Rizvi et al, ...colorectal cancers have been shown to correlate with the density of ... See full document
41
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
... to PD-L1 inhibition was noted [55, ...to PD-1/PD-L1 in- hibition in ...of PD-L1 synthesis and expression in NSCLC ...to PD-L1 blockade ...of ... See full document
6
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
... of PD-1/PD-L1 and the immune response associated with the PD-1 axis in the datamining analysis, we investigated whether blockade of the PD-1 axis could generate an ... See full document
13
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
... receiving PD-1/PD-L1 inhibitors demonstrated higher risk of all-grade rash, pruritus, hypothyroidism, hyper- thyroidism, colitis, aminotransferase elevations, and pneumonitis but lower risk of ... See full document
18
From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
... with PD-L1 expression on 5% of immune cells (IC2/3 population; n = 234) in accordance with the pre- specified hierarchical testing ...Table 1) ...of PD-L1 status, and ... See full document
15
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
... emerging clinical biomarker of response to ICIs is the tumor mutational burden (TMB), defined as the total number of mutations per coding area of a tumor ...with clinical benefit from ICI therapy within ... See full document
11
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
... of PD-L1 (compared to the apo-structure), which is partly different to that induced by the PD-1 ...the PD-1/PD-L1 complex, Tyr56 of PD-L1 is rotated ... See full document
13
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
... for immunotherapy; the tumor types most frequently associated with PNSs (such as small-cell lung cancers, gynecological cancers and thymic tumors) are not gener- ally treated with immune checkpoint ... See full document
12
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
... human cancer type [14, 19–21]. Indeed, many of the cancers against which immune checkpoint therapy is effective (e.g., melanoma, non-virus-associated Merkel cell carcinoma and microsatellite unstable neoplasms) ... See full document
5
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
... for PD-L1 positivity using four different PD-L1 IHC assays, 22C3, 28-8, SP263 and ...in clinical routine for the selection of lung cancer ...detect PD-L1 expression on ... See full document
12
PD-L1 expression in human cancers and its association with clinical outcomes
... of PD-L1 has technical issues, and the results may not accurately reflect the real PD-L1 expression ...of PD-L1 expression in tumors is affected by temporal and spatial factors, ... See full document
17
The association of genomic lesions and PD 1/PD L1 expression in resected triple negative breast cancers
... for PD-1 and PD-L1 protein expression by using validated antibodies and established scoring methods that included PD-L1 staining intensities on tumor and non-tumor cells ...of ... See full document
15
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
... of PD-L1 expression on tumors were assessed from Nogu- chi et ...of PD-L1. They found that abnormally high expression of PD-L1, but not levels of PD-L1 expres- sion ... See full document
8
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
... higher PD-L1 expression ...to PD-1/PD-L1 checkpoint blockades may also be observed in glioblas- ...of PD-L1 and IDO, downregulate MHC and costimulatory molecules, ... See full document
13
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy
... Angiomyolipomas (AMLs) are neoplasms thought to arise from pericites, hence belonging to the family of perivasci- ular epithelioid cell neoplasms (PEComas). Though asso- ciated with tuberous sclerosis complex (TSC), most ... See full document
7
Related subjects